版本:
中国

BRIEF-Merck enters exclusive worldwide license agreement with Teijin Pharma

May 25 Merck & Co Inc:

* Merck enters exclusive worldwide license agreement with Teijin Pharma for investigational antibody candidate targeting TAU

* Merck & Co Inc - under terms of agreement Merck will have exclusive world-wide rights to develop, manufacture and commercialize anti-TAU antibody.

* Says Teijin Pharma will receive royalties on product sales and retains an option to co-promote an approved product in Japan

* Merck & Co Inc - will make an upfront payment to Teijin Pharma who is also eligible to receive development, regulatory and sales milestone payments

* Merck & Co Inc - Merck will make an upfront payment to Teijin Pharma who is eligible to receive development, regulatory and sales milestone payments Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐